Shanghai Pharmaceuticals Holding Co., Ltd

2607.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2607.HK stands at 65.2B. In comparison, 1099.HK has a market cap of 56.8B. Regarding current trading prices, 2607.HK is priced at HK$11.84, while 1099.HK trades at HK$18.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2607.HK currently has a P/E ratio of 9.25, whereas 1099.HK's P/E ratio is 7.44. In terms of profitability, 2607.HK's ROE is +0.06%, compared to 1099.HK's ROE of +0.09%. Regarding short-term risk, 2607.HK is more volatile compared to 1099.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2607.HK.

2607.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2607.HK stands at 65.2B. In comparison, 2192.HK has a market cap of 10.5B. Regarding current trading prices, 2607.HK is priced at HK$11.84, while 2192.HK trades at HK$14.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2607.HK currently has a P/E ratio of 9.25, whereas 2192.HK's P/E ratio is 30.43. In terms of profitability, 2607.HK's ROE is +0.06%, compared to 2192.HK's ROE of +0.07%. Regarding short-term risk, 2607.HK is less volatile compared to 2192.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2607.HK.

2607.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2607.HK stands at 65.2B. In comparison, 1931.HK has a market cap of 3.2B. Regarding current trading prices, 2607.HK is priced at HK$11.84, while 1931.HK trades at HK$2.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2607.HK currently has a P/E ratio of 9.25, whereas 1931.HK's P/E ratio is 10.53. In terms of profitability, 2607.HK's ROE is +0.06%, compared to 1931.HK's ROE of +0.07%. Regarding short-term risk, 2607.HK is less volatile compared to 1931.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2607.HK.

2607.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2607.HK stands at 65.2B. In comparison, 2289.HK has a market cap of 761.4M. Regarding current trading prices, 2607.HK is priced at HK$11.84, while 2289.HK trades at HK$7.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2607.HK currently has a P/E ratio of 9.25, whereas 2289.HK's P/E ratio is 13.06. In terms of profitability, 2607.HK's ROE is +0.06%, compared to 2289.HK's ROE of +0.09%. Regarding short-term risk, 2607.HK is more volatile compared to 2289.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2607.HK.

2607.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2607.HK stands at 65.2B. In comparison, 9955.HK has a market cap of 682M. Regarding current trading prices, 2607.HK is priced at HK$11.84, while 9955.HK trades at HK$1.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2607.HK currently has a P/E ratio of 9.25, whereas 9955.HK's P/E ratio is -1.10. In terms of profitability, 2607.HK's ROE is +0.06%, compared to 9955.HK's ROE of -0.12%. Regarding short-term risk, 2607.HK is less volatile compared to 9955.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2607.HK.

2607.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2607.HK stands at 65.2B. In comparison, 0718.HK has a market cap of 183.8M. Regarding current trading prices, 2607.HK is priced at HK$11.84, while 0718.HK trades at HK$0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2607.HK currently has a P/E ratio of 9.25, whereas 0718.HK's P/E ratio is -0.25. In terms of profitability, 2607.HK's ROE is +0.06%, compared to 0718.HK's ROE of +0.60%. Regarding short-term risk, 2607.HK is less volatile compared to 0718.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2607.HK.

2607.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2607.HK stands at 65.2B. In comparison, 0673.HK has a market cap of 147.5M. Regarding current trading prices, 2607.HK is priced at HK$11.84, while 0673.HK trades at HK$0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2607.HK currently has a P/E ratio of 9.25, whereas 0673.HK's P/E ratio is -3.33. In terms of profitability, 2607.HK's ROE is +0.06%, compared to 0673.HK's ROE of -0.89%. Regarding short-term risk, 2607.HK is less volatile compared to 0673.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2607.HK.

2607.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2607.HK stands at 65.2B. In comparison, 8372.HK has a market cap of 95.2M. Regarding current trading prices, 2607.HK is priced at HK$11.84, while 8372.HK trades at HK$0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2607.HK currently has a P/E ratio of 9.25, whereas 8372.HK's P/E ratio is 11.90. In terms of profitability, 2607.HK's ROE is +0.06%, compared to 8372.HK's ROE of +0.08%. Regarding short-term risk, 2607.HK is more volatile compared to 8372.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2607.HK.

2607.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2607.HK stands at 65.2B. In comparison, 0401.HK has a market cap of 40.9M. Regarding current trading prices, 2607.HK is priced at HK$11.84, while 0401.HK trades at HK$0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2607.HK currently has a P/E ratio of 9.25, whereas 0401.HK's P/E ratio is -7.30. In terms of profitability, 2607.HK's ROE is +0.06%, compared to 0401.HK's ROE of -0.47%. Regarding short-term risk, 2607.HK is more volatile compared to 0401.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2607.HK.